Immunosuppressive Strategies in Kidney Xenotransplantation with an Emphasis on Complement Inhibition

Area of Science:

• Transplantation immunology
• Xenotransplantation research
• Organ replacement strategies

Background:

• Kidney xenotransplantation is a promising solution for the organ donor shortage, with advances in pig genetics and immunotherapy.
• Successful clinical trials in deceased and living recipients show genetically modified pig kidneys can sustain human renal function.

Purpose of the Study:

• To review the current state of kidney xenotransplantation, focusing on immune challenges and potential solutions.
• To highlight the effectiveness of genetic modifications in overcoming hyperacute rejection.
• To discuss the persistent immune responses and novel challenges like proteinuria.

Main Methods:

• Review of recent clinical experiences and experimental data in kidney xenotransplantation.
• Analysis of genetic modifications in donor pigs, including GGTA1 deletion.
• Evaluation of immunosuppressive strategies, including B-cell depletion and costimulation blockade.
• Assessment of complement activation pathways and their inhibition.
• Investigation of proteinuria development and its implications.

Main Results:

• Genetic modification, particularly GGTA1 deletion, effectively prevents hyperacute rejection.
• Xenotransplantation triggers aggressive innate and adaptive immune responses.
• Standard immunosuppression is insufficient; intensified regimens with B-cell depletion and costimulation blockade are necessary.
• Complement activation persists despite genetic modifications, necessitating targeted inhibition.
• Early-onset nephrotic-range proteinuria is a significant challenge, potentially impacting graft survival.

Conclusions:

• Hyperacute rejection is overcome, but sustained immune responses and complement activation require intensive immunosuppression.
• Proteinuria is an emerging complication affecting graft function and immunosuppressive drug efficacy.
• Future success relies on integrated strategies: genetic engineering, costimulation blockade, and complement inhibition.